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Abstract
Background: Hypoxia-inducible factor-1a (HIF-1a), a critical transcription factor to reduced O2 availability, has been
demonstrated to be extensively involved in tumor survival, aggressive progression, drug resistance and
angiogenesis. Thus it has been considered as a potential anticancer target. Triptolide is the main principle
responsible for the biological activities of the Traditional Chinese Medicine tripterygium wilfordii Hook F. Triptolide
possesses great chemotherapy potential for cancer with its broad-spectrum anticancer, antiangiogenesis, and drug-
resistance circumvention activities. Numerous biological molecules inhibited by triptolide have been viewed as its
possible targets. However, the anticancer action mechanisms of triptolide remains to be further investigated. Here
we used human ovarian SKOV-3 cancer cells as a model to probe the effect of triptolide on HIF-1a.
Results: Triptolide was observed to inhibit the proliferation of SKOV-3 cells, and meanwhile, to enhance the
accumulation of HIF-1a protein in SKOV-3, A549 and DU145 cells under different conditions. Triptolide did not
change the kinetics or nuclear localization of HIF-1a protein or the 26 S proteasome activity in SKOV-3 cells.
However, triptolide was found to increase the levels of HIF-1a mRNA. Unexpectedly, the HIF-1a protein induced by
triptolide appeared to lose its transcriptional activity, as evidenced by the decreased mRNA levels of its target
genes including VEGF, BNIP3 and CAIX. The results were further strengthened by the lowered secretion of VEGF
protein, the reduced sprout outgrowth from the rat aorta rings and the inhibitory expression of the hypoxia
responsive element-driven luciferase reporter gene. Moreover, the silencing of HIF-1a partially prevented the
cytotoxicity and apoptosis triggered by triptolide.
Conclusions: The potent induction of HIF-1a protein involved in its cytotoxicity, together with the suppression of
HIF-1 transcriptional activity, indicates the great therapeutic potential of triptolide as an anticancer drug.
Meanwhile, our data further stress the possibility that HIF-1a functions in an unresolved nature or condition.
Background
Hypoxia-inducible factor-1a (HIF-1a) is a critical tran-
scription factor responsible for adaptive responses of
cancer cells to reduced O2 availability [1]. Through
modulation of the expression of at least 70 genes, HIF-
1a is extensively involved in tumor survival, aggressive
progression, drug resistance and angiogenesis [2].
Elevated levels of HIF-1a protein are observed in var-
ious human primary and metastatic cancers, either as
direct results of intratumoral hypoxia or secondary to
genetic alterations in oncogenes or tumor suppressor
genes [3,4]. Those cancers are generally relatively poorly
responsive to chemotherapy or radiotherapy with poor
prognosis [5]. Thus, HIF-1a has been proposed as a
promising anticancer target [6]. On the other hand,
HIF-1a(-/-) tumors have also been demonstrated to
show a feature of faster proliferation and more obvious
resistance to apoptosis than the HIF-1a(+/+) counter-
parts [7], suggesting a possibility that HIF-1a may have
unknown function(s) or exert its transcriptional activity
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Triptolide is an effective principle of the Traditional
Chinese Medicine tripterygium wilfordii Hook F that has
been used to treat autoimmune and inflammatory
diseases for centuries [8,9]. Triptolide possesses broad-
spectrum anticancer, antiangiogenesis, and drug-
resistance circumvention activities [10-13]. Moreover,
our recent study shows that a novel C14-hydroxyl sub-
stituted triptolide derivative elicits selective anticancer
effects, specifically against ovarian and prostate cancers
in nude mice xenograft models, with reduced toxicity as
compared to the parent triptolide [14]. Nevertheless, the
anticancer action mechanisms of triptolide are compli-
cated and remain to be further investigated. Triptolide
downregulates various proteins including heat shock
protein 70, Bcr-Abl, survivin, Mcl-1, Akt, c-myc, cyclin
A/cdk2, cyclin B/cdc2, cyclin D1 and pRB, which may
contribute to its anticancer activity under specific condi-
tions [12,15,16]. In addition, inhibition of nuclear factor
B activation by triptolide is also assoctiated with its
potentiation of TNF related apoptosis-inducing ligand-
induced anticancer effects [17]. Notably, however, trip-
tolide enhances the levels of p53 protein in p53-wild
type human tumors but lowers its transcriptional activ-
ity, resulting in the reduced expression of p21 protein
[18-20].
Based on the discovery of selective anticancer activity
of the new triptolide analogue in human ovarian and
prostate cancer xenograft models [14], in this current
study, we used human ovarian SKOV-3 cancer cells as a
model to further investigate the mechanisms of action
of triptolide. Triptolide was unexpectedly revealed to
enhance the cellular accumulation of HIF-1a protein
with reduced transcriptional activity. The impact of trip-
tolide on HIF-1a contributes to its partial anticancer
effect. These results from triptolide further stress the
possibility that HIF-1a f u n c t i o n si na nu n r e s o l v e dn a t -
ure or condition.
Results
Triptolide elicits cytotoxicity and increases HIF-1a
accumulation
Triptolide has been demonstrated to possess potent
antitumor and antiangiogenic activities [12,21]. HIF-1a
is an important regulator of tumor angiogenesis [22]. To
find a proper model to examine the effect of triptolide
on HIF-1a protein, we first tested the sensitivity of
human ovarian cancer SKOV-3 cells to this compound
because the cells are highly sensitive, both in vitro and
in vivo, to triptolide analogues [14].
As expected, triptolide elicited potent concentration-
dependent cytotoxicity in SKOV-3 cells with an averaged
IC50 value of 10.24 nM for 72-h treatments (Fig. 1A).
Unexpectedly, however, triptolide led to significant accu-
mulation of cellular HIF-1a protein in a concentration-
dependent manner following the 12-h exposure of
SKOV-3 cells at normoxia (Fig. 1B). The similar results
were reproducible in SKOV-3 cells exposed to hypoxia or
mimic hypoxia with cobalt chloride (CoCl2) [23] (Fig. 1B)
or in hypoxic human lung A549 and prostate DU145
cancer cells (Fig. 1C and 1D). The data indicate that the
increase in the cellular accumulation of HIF-1a protein
by triptolide is independent of the environmental oxygen
pressure and the cell type, suggesting that it is an inher-
ent capability of this agent.
To function as a transcription factor, HIF-1a heterodi-
merizes HIF-1b that is constitutively expressed [2]. The
treatment with triptolide did not change the levels of
HIF-1b in normoxic, hypoxic or CoCl2-treated SKOV-3
cells (Fig. 1B). Moreover, co-immunoprecipitation
further showed that triptolide did not impair the bind-
ing of HIF-1a to HIF-1b (Fig. 1E). In addition, triptolide
just marginally changed the levels of HIF-2a (Fig. 1F),
another hypoxia-inducible factor (HIF) alpha subunit
that has various overlapped targeting genes with HIF-1a
[24].
Triptolide increases HIF-1a accumulation but does not
change its kinetics and cellular localization at hypoxia
In response to acute hypoxia, HIF-1a protein rapidly
accumulates in the cells due to the inactivation of oxy-
gen-sensitive prolyl hydroxylase [25]; but prolonged
hypoxia initiates CHIP (a prolyl hydroxylase -indepen-
dent E3 ligase) -mediated HIF-1a degradation and low-
ers its cellular levels [26]. This typical first-up-and-then-
down kinetics of HIF-1a protein also occurred in
SKOV-3 cells at hypoxia (Fig. 2A and 2B). To clarify
whether triptolide affects such kinetics, we exposed
hypoxic SKOV-3 cells to this compound. The result
showed that triptolide, though increasing the amount at
each corresponding time-point, did not change the
kinetic trend of the accumulation and degradation of
HIF-1a protein (Fig. 2A and 2B). Moreover, HIF-1a
protein was also localized in the nuclei of the hypoxic
SKOV-3 cells treated with triptolide (Fig. 2C), just as
generally expected [27,28]. These data critically suggest
that triptolide may not interfere with HIF-1a protein
degradation, either oxygen-dependent or oxygen-inde-
pendent, when collectively considering the increased
levels of HIF-1a protein at normoxia (Fig. 1B).
Triptolide does not affect the 26 S proteasome activity
but enhances the levels of HIF-1a mRNA
To validate the effect of triptolide on HIF-1a protein
degradation, we detected whether triptolide inhibited
the activity of 26 S proteasome, which is crucial degra-
dation machinery for HIF-1a protein [29]. Triptolide
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Page 2 of 11Figure 1 Triptolide inhibited the proliferation of SKOV-3 cells and induced the accumulation of HIF-1a protein. A.S K O V - 3c e l l sw e r e
exposed to triptolide of gradient concentrations for 72 h. The proliferation inhibition was determined by SRB assays. B. SKOV-3 cells at normoxia
(upper panel), 1% O2 hypoxia (middle panel) or CoCl2 (150 μM) mimic hypoxia (lower panel) were treated with tiptolide for 12 h and then
subjected to standard Western blotting analyses for the levels of HIF-1a and HIF-1b proteins. C and D. A549 (C) and DU145 (D) cells at 1% O2
hypoxia were treated with tiptolide for 12 h and Western blotting analyses were done as in B. E. SKOV-3 cells at CoCl2 (150 μM) mimic hypoxia
were treated with tiptolide at 1000 nM for 12 h. Then the cells were subjected to Western blotting for the levels of HIF-1a, HIF-1b proteins (left
panel); or the cells were used to do co-immunoprecipitation assays for the binding between HIF-1a and HIF-1b (middle and right panels). F.
SKOV-3 cells at 1% O2 hypoxia were treated with tiptolide at gradient concentrations for 12 h. Then the cells were subjected to Western blotting
for the levels of HIF-2a proteins. All the experiments were performed three times and the representative results were presented.
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Page 3 of 11was not shown to apparently inhibit the chymotrypsin-
like activity of 26 S proteasome in either SKOV-3 cells
or their cell lysates treated with triptolide, even up to
10000 nM. In contrast, the positive control MG132 dra-
matically inhibited the 26 S proteasome activity (Fig. 3A
and 3B).
To further dissect the possible cause of HIF-1a induc-
tion by triptolide, we used semi-quantitative RT-PCR
and quantitative real-time PCR assays for the levels of
HIF-1a mRNA in the triptolide-treated SKOV-3 cells.
The results showed that triptolide enhanced the levels
of HIF-1a mRNA in a concentration-dependent manner
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Figure 2 Triptolide did not change the cellular kinetics and nuclear localization of HIF-1a protein in response to hypoxia. A and B.
SKOV-3 cells were exposed to 1% O2 hypoxia in the presence or absence of triptolide (100 nM) for the indicated time periods. Then standard
western blotting analyses were performed for the levels of HIF-1a protein (A). Adobe Photoshop CS2 version 9.0.2 was used for relative semi-
quantification of the HIF-1a band intensity, which was normalized with b-Actin as the internal control. The results from three separate
experiments were expressed as mean ± SD (B). C. SKOV-3 cells were treated as described in the Materials and Methods section and then
subjected to immunofluorescence analyses for the localization of HIF-1a protein. The representative images were from three separate
experiments with similar results.
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Page 4 of 11(Fig. 3C and 3D), which may be responsible for the
HIF-1a accumulation.
Triptolide reduces the transcriptional activity of HIF-1a
protein
HIF-1a protein functions as a critical transcription fac-
tor in adaptive response to hypoxia [1]. To determine
whether triptolide also increases the transcriptional
activity of HIF-1a protein when enhancing its accumu-
lation, we examined the expression levels of its several
target genes including vascular endothelial growth fac-
tor (VEGF), BCL2 and adenovirus E1B 19-kDa-inter-
acting protein 3 (BNIP3) and carbonic anhydrase IX
(CAIX) [30,31] in the triptolide-treated SKOV-3 cells.
Unexpectedly, however, the results revealed that the
mRNA levels of the three genes did not increase but
decreased typically in a concentration-dependent man-
ner (Fig. 4A). Moreover, the secretion of VEGF pro-
tein, a critical angiogenesis factor, also reduced
(Fig. 4B). Triptolide was further revealed to obviously
inhibit the sprout outgrowth from the rat aorta rings
(Fig. 4C), indicating its antiangiogenesis capability as
previously reported [10,11,21].
To confirm whether triptolide reduces the transcrip-
tional activity of HIF-1a protein, we used the hypoxia
responsive element (HRE)-driven luciferase reporter
gene assays. After failure with SKOV-3 or A549 cells
due to the low transfection efficiency, we co-transfected
the HRE luciferase reporter plasmid and the renilla luci-
ferase reporter vector pGL-3 into MCF-7 cells for 24 h.
Then the cells were treated with triptolide for additional
12 h. Triptolide reduced the luciferase-elicited fluores-
cence in a concentration-dependent fashion, and at
1000 nM of triptolide, the fluorescence almost lowered
to the basal level (Fig. 4D). Collectively, the above evi-
dence arising from all the levels of the transcription of
the target genes, the reporter gene and the subsequent
biological effects indicates that triptolide, though
increasing the cellular accumulation of HIF-1a protein,
reduces its transcriptional function.
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Figure 3 Triptolide did not affect the 26 S proteasome activity but enhanced the levels of HIF-1a mRNA. A. SKOV-3 cells were treated
with triptolide for 12 h under hypoxia condition and then harvested for the detection of 26 S proteasome activity as described in the Materials
and Methods. B. The lysates of SKOV-3 cells were incubated in the presence or absence of triptolide and then assayed for the 26 S proteasome
activity. C and D. The levels of HIF-1a mRNA from reverse transcription -PCR (C) and real-time PCR (D) analyses in the hypoxic SKOV-3 cells
treated with triptolide for 12 h. The levels of HIF-1a mRNA were normalized with b-actin mRNA expression; columns, mean of three
independent experiments; bars, SD. The significant difference between triptolide-treated groups and hypoxia-control groups was analyzed by
Student t test. * P < 0.05.
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Page 5 of 11The action of triptolide on HIF-1a contributes at least
partially to its anticancer activity
To demonstrate whether the effect of triptolide on HIF-
1a is associated with its anticancer activity, we knocked
down HIF-1a with three specific HIF-1a siRNAs in
SKOV-3 cells (Fig. 5A). SRB assays showed that the
silencing of HIF-1a partially prevented the cytotoxicity
of triptolide (Fig. 5B). Consistently, triptolide induced
much less apoptosis in the HIF-1a-silenced cells than in
the control cells (Fig. 5C and 5D). These data clearly
reveal a close association of the effect of triptolide on
HIF-1a with its anticancer activity.
Discussion
Overexpression of HIF-1a in human cancers is usually
correlated with poor prognosis and poor therapeutic
response [32]. HIF-1a has been considered as a poten-
tial therapeutic target [33]. Nevertheless, there are also
reports that HIF-1a null tumors grow unexpectedly fast,
and that tumor cells with HIF-1a(-/-) tumors are more
proliferative and less apoptotic than those with HIF-1a
( + / + )e v e nw h e nt u m o rv e s s e lf o r m a t i o nw a si m p a i r e d
[7]. These paradoxical observations seem to suggest that
the roles of HIF-1a in tumor development and/or in
cancer therapy are conditional and that the conditions
remain to be further clarified so that this important
tumor-related factor can be better employed. Our find-
ings in this current study further stress such conditional
or stimulation-dependnent changes as the potent antic-
ancer agent triptolide has been revealed to increase the
cellular accumulation of HIF-1a protein that contributes
partially to its anticancer activity.
Triptolide has been well documented to possess potent,
broad-spectrum antitumor activity and to inhibit angio-
genesis [10,34]. Our present study showed that triptolide
enhanced the cellular accumulation of HIF-1a protein in
SKOV-3, A549 and DU145 cancer cells at normoxia,
hypoxia or CoCl2-mimic hypoxia. However, triptolide did
not apparently change the protein levels of HIF-1b and
HIF-2a and the binding of HIF-1a to HIF-1b. Triptolide
did not change the kinetics or localization of HIF-1a pro-
tein in SKOV-3 cells exposed to hypoxia. Consistently,
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Figure 4 Triptolide decreased the transcription activity of HIF-1a protein. A. SKOV-3 cells were cultured under normoxic or hypoxic
conditions in the presence or absence of triptolide for 12 h. The mRNA levels of VEGF, BNIP3 and CAIX were analyzed by real-time PCR and
normalized with b-actin mRNA expression. B. ELISA assays were done for VEGF secretion from the SKOV-3 cells treated as in A. C. Triptolide
inhibited new microvessel outgrowth arising from rat aorta rings. The representative images were from three separate experiments with similar
results. D. MCF-7 cells were transiently transfected with the HRE-luciferase and renilla-luciferase reporter plasmids and then cultured at normoxia
or hypoxia in the presence or absence of triptolide for 12 h followed by assays for luciferase activity. Data shown in A, B and D were expressed
as mean ± SD, n = 3. The significant difference between triptolide-treated groups and hypoxia-control groups was analyzed by Student t test.
* P < 0.05.
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Page 6 of 11triptolide did not impair the 26 S proteasome activity. The
increased levels of HIF-1a mRNA could be responsible for
the accumulation of HIF-1a protein induced by triptolide
in SKOV-3 cells. Unexpectedly, the triptolide-increased
HIF-1a protein seems to lose its transcriptional activity, as
evidenced by the decreased mRNA levels of its target
genes including VEGF, BNIP3 and CAIX (the transcrip-
tion of which is generally promoted by HIF-1a [30,31]).
The results were further strengthened by the lowered
secretion of VEGF protein, the reduced sprout outgrowth
from the rat aorta rings and the inhibitory expression of
the HRE luciferase reporter gene. More importantly, the
partial prevention of cytotoxicity and apoptotic induction
of triptolide by HIF-1a silencing indicates the contribution
of the accumulated HIF-1a protein to the anticancer
action of this compound.
Several important points arise from those results: (1)
The apparent association of the increased HIF-1a protein
induced by triptolide with its anticancer activity challenges
the general notion that the downregulation of HIF-1a pro-
tein elicits anticancer and antiangiogenic effects, as many
HIF-1a inhibitors do [35,36]. (2) The HIF-1a protein in
the triptolide-treated cells appears to have some additional
non-transcriptional function because it loses its transcrip-
tional activity but is indeed involved in the anticancer and
antiangiogenic actvity of triptolide in our case. Another
possibility is that the apparently decreased transcriptional
activity of the triptolide-induced HIF-1a protein may be
subsequent to the inhibitory effect of triptolide on RNA
polymerase II (RNA Pol II). As a critical general transcrip-
tion factor, RNA Pol II has been demonstrated to be
inhibited by triptolide, which could contribute to its global
transcriptional arrest [37,38]. The inhibition of RNA Pol II
impairs the transcription-promoting function of HIF-1,
thus reducing the transcriptional activity of the triptolide-
induced HIF-1a protein. Actually, triptolide has been
Figure 5 HIF-1a silencing partially prevented the proliferation inhibition and apoptosis induction by triptolide. A. siRNAs targeting three
different sequences of the HIF-1a gene were used to effectively silence this gene in SKOV-3 cells (Western blotting). GFP siRNA was used as
scrambled control. B. The SKOV-3 cells transfected with HIF-1a or GFP siRNA were treated with triptolide for 48 h and then subjected to SRB
assays for the proliferation inhibition. C. The SKOV-3 cells transfected with HIF-1a or GFP siRNA were treated with triptolide for 36 h and then
assayed for apoptotic induction by flow cytometry as described in the Materials and Methods section. The representative histograms were from
three independent experiments with similar results. D. The apoptosis rate from C. Data shown in B and D were expressed as mean ± SD, n = 3.
The significant difference between triptolide-treated groups and hypoxia-control groups was analyzed by Student t test. * P < 0.05.
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Page 7 of 11reported to similarly lead to the elevated levels of wild-
type p53 protein with reduced transcriptional activity
[18-20]. (3) The enhancement of HIF-1a mRNA by tripto-
lide may be a compensatory response by the tumor cells in
an effort to maintain HIF-1a transcriptional activity. Or,
subsequent to its RNA Pol II inhibition, the transcription
of some factor(s) responsible for degrading HIF-1a mRNA
may be arrested, finally disrupting the degradation
machinery and resulting in the accumulation of HIF-1a
mRNA. This is potentially similar to the effect of actino-
mycin D, an inhibitor of transcription, on the degradation
of HIF-1a protein. Actinomycin D was found to lead to
super-induction of HIF-1a protein by inhibiting the tran-
scription of some unidentified factor(s) responsible for
degrading HIF-1a protein (transcription-dependent degra-
dation) [39]. (4) Triptolide could be used as a tool com-
pound to probe the potential new function of HIF-1a
protein due to its unique action. (5) The interference of
triptolide with HIF-1a is one of its possible anticancer
and/or antiangiogenesis mechanisms.
Those points obviously deserve further investigation.
Hypoxia is prevalent in solid tumors and HIF-1a is a
critical regulator of tumor hypoxia adaption [40]. Clarifi-
cation of the conditions or stimulations required for
specific HIF-1a activities (for instance, promoting or
suppressing the expression of specific genes or gene
sets) may greatly help the development of HIF-1a-tar-
geted therapeutics and the monitor of cancer progres-
sion and prognosis. Moreover, demonstration of the
function(s) of HIF-1a in addition to its transcriptional
activity, if any indeed as shown in this study, will give
new insights into hypoxia biology. On the other hand,
triptolide is a promising anticancer lead compound and
its chemical modifications are actively ongoing [14,41].
The discovery of its unique impact on HIF-1a suggests
another possible anticancer mechanism. Therefore, the
questions of how triptolide increases the levels of HIF-
1a mRNA, why and how it reduces the transcriptional
activity of HIF-1a protein need thoroughly elucidating.
Conclusions
In summary, triptolide was found to increase the levels
of HIF-1a mRNA and protein and to reduce HIF-1a
transcriptional activity, which contributes to its antitu-
mor effect partially. These data, on one hand, propose a
new potential anticancer mechanism of triptolide, and
stress a possibility that HIF-1a f u n c t i o n si na nu n r e -
solved nature or condition on the other.
Methods
Chemicals
Triptolide used in our experiments was prepared from
tripterygium wilfordii Hook F with the following
procedure. First, the powder of tripterygium wilfordii
bark was extracted with ethanol to obtain its ethanol
extracts. The ethanol extracts were next extracted with
chloroform to get chloroform extracts. Then, we puri-
fied the chloroform extracts on silica gel columns with a
mobile phase of chloroform to get triptolide crude.
Finally, by recrystalizing the triptolide crude with ether,
we obtained triptolide with the HPLC purity of more
than 99%. MG132 was purchased from Sigma (St.
Louise, MO, USA). All the compounds were dissolved at
10 mM in dimethyl sulfoxide (Sigma, St. Louise, MO,
USA) as stock solution. The stock solutions were kept
in aliquot at -20°C (triptolide) or at -80°C (MG132) and
thawed immediately prior to each experiment.
Cell culture
Human ovarian SKOV-3, lung A549, breast MCF-7 and
prostate DU145 cancer cells were obtained from the
American Type Culture Collection (Manassas, VA,
USA). Cells were cultured in DMEM (SKOV-3 and
MCF-7), F12 (A549), or RPIM-1640 medium (DU145)
(Life Technologies, Grand Island, NY USA) supplemen-
ted with 15% FBS (Life Technologies, Grand Island, NY,
USA) at 37°C in a humidified atmosphere containing 5%
CO2. Hypoxia treatment was performed by placing cells
in a CO2 Water Jacketed Incubator (Thermo Forma,
Model 3110 series, OH, USA) flushed with a mixture of
1% O2,5 %C O 2 and 94% N2.
Cytotoxicity assays
The cytotoxicity of triptolide was examined by sulfor-
hodamine B (SRB) assays as described previously [42].
Briefly, cells in 96-well plates were treated in triplicate
with gradient concentrations of triptolide at 37°C for
72 h, and then assessed with SRB (Sigma, St. Louise,
MO, USA). The absorbance at 560 nM was detected
with a plate reader (SpectraMax, Molecular Devices,
CA, USA). The growth inhibition rate was calculated
as (1-A560 treated/A560 control)×1 0 0 % .
Western blotting analyses
Cells were lyzed in 1 × SDS lysis buffer [50 mM Tris-
HCl (pH6.8), 100 mM DTT, 2% SDS, 0.1% bromphenol
blue, 10% glycerol] and then boiled for 10-15 min. Wes-
tern blotting analyses were performed as previously
described [43] using appropriate antibodies including
anti-HIF-1a (BD, Franklin Lakes, NJ, USA), anti-HIF-1b
(BD, Franklin Lakes, NJ, USA), anti-HIF-2a (R&D Sys-
tems, MN, USA), anti-b-actin (Beyotime, Haimen,
China), and the levels of cellular proteins were visua-
lized with peroxidase-coupled secondary antibodies
(Dingguo, Beijing, China) using ECL-plus kit from
Amersham Biosciences (Buckinghamshire, UK).
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Page 8 of 11Cell immunofluorescence
Immunofluorescence analyses were performed as
described previously [27]. Briefly, Cells (0.5 × 10
5)w e r e
seeded onto cover slips in 24-well plates and exposed to
hypoxia for 12 h treated with or without triptolide
simultaneously. One slip was left at normoxia as control.
Then, the cells were fixed, washed, permeabilized,
washed and blocked. After that, the cells were sequen-
tially incubated with anti-HIF-1a antibody (BD, Franklin
Lakes, NJ), washed, and incubated with Alexa Fluor
488-conjugated anti-mouse secondary antibody (Invitro-
gen, Carlsbad, CA). Finally, the cover slips were photo-
graphed with a Leica TCS SP2 confocal microscope
(Leica, Wetzlar, Germany).
Co-immunoprecipitation
Cells treated with 150 μMC o C l 2 with or without
1000 nM triptolide for 12 h were collected for
co-immunoprecipitation. Briefly, cells were lyzed with
NP40 lysis buffer (Beyotime, Haimen, China) for
co-immunoprecipitation. Followed by centrifugation, the
supernatants were pre-cleared with 20 μLp r o t e i nG
agarose beads (Beyotime, Haimen, China) coupled with
m o u s eo rr a b b i tI g Gf o ro v e r2h ;a n dt h e nw e r e
exposed to 20 μL protein G agarose beads coupled with
the indicated antibodies for over 6 h. The beads were
w a s h e d3t i m e sw i t h1m LP B Sf o r2 0m i ne a c h .T h e
precipitants were dissolved with the SDS loading buffer
for Western blotting analyses.
Assays for proteasome activity
The activity of 26 S proteasome was determined as
described previously [44]. Briefly, cells were harvested
and washed with PBS (pH 7.4), pelleted by centrifuga-
tion and then lyzed in Lysis buffer (pH 7.5) [50 mM
Hepes, 5 mM EDTA, 150 mM NaCl, and 1% Triton] on
ice for 30 min. After that, whole cell lysates were centri-
fugated at 12000 ×g and 4°C for 10 min. The superna-
tants were aspirated. The reaction buffer (pH 8)
contained 20 mM HEPES, 0.5 mM EDTA, and 0.035%
SDS. Reaction mixtures in a total volume of 100 μL
including reaction buffer (85 μL), cell extracts (5 μL),
and the fluorogenic proteasome substrate Z-LLL-AMC
(10 μL) (Calbiochem, La Jolla, CA) were incubated at
37°C for 1 h. For cell-free assays (the cell lysates were
treated with triptolide), triptolide was added into the
mixtures. For cellular assays (Cells were treated with
triptolide and then subjected to lysis), the protein con-
centration was determined by the Micro BCA protocol
(Pierce, Rockford, USA) and added the cell extracts with
the same protein concentration into the mixtures. Clea-
vage activity was monitored continuously by detecting
free 7-amido-4-methylcoumarin with a fluorescence
plate reader (Gemini, Molecular Devices, USA) at 380/
460 nm. As controls for drug studies, Z-LLL-AMC was
incubated with drugs in Reaction buffer without cell
extracts and measurements of proteasome activity were
corrected when necessary.
Luciferase activity assays
For luciferase activity assays, cells were co-transfected
with 60 ng HRE luciferase reporter plasmid and renilla
luciferase reporter vector pGL-3 per well using Lipofec-
tamine™2000 for 24 h. Cells were treated with triptolide
for further 12 h and harvested for the luciferase activity
analyses using the dual luciferase reporter assay system
(Beyotime, Haimen, China). Luminence was measured
with GloMax® 96 Microplate LuminometerW/Dual
injectors (Promega, Madison, USA). The firefly lucifer-
ase luminescence activity was normalized to the control
renilla luciferase activity.
Reverse transcription-PCR analyses
Cells were treated with triptolide for the indicated time.
Total RNA was isolated with the Trizol reagent. Total
RNA was reverse transcribed using Superscript™III
reverse transcriptase and cDNA was used for PCR with
the following primers (synthesized by Sanggon Corpora-
tion, Shanghai, China): b-actin, 5’-TGA CGG GGT CAC
CCA CAC TGT GCC CAT CTA-3’(forward), 5’-CTA
GAA GCA TTG CGG TCG ACG ATG GAG GG-
3’(backward); and HIF-1a,5 ’-CTC AAA GTC GGA CAG
CCT CA-3’(forward), 5’-CCC TGC AGT AGG TTT
CTG CT-3’(backward). Amplification was done for 35
cycles, each with denaturation at 94°C for 1 min, anneal-
ing at 55°C for 1 min and extension at 72°C for 1 min.
The products were analyzed using agarose gel electro-
phoresis and visualized by ethidium bromide staining.
Real time-PCR Analyses
Cells were lyzed with the Trizol reagent and total RNA
was isolated with chloroform and isopropyl alcohol.
One-microgram RNA was subjected to reverse tran-
scription with the RT reagent kit (TaKaRa, Dalian,
China) according to the manufacturer’s instructions.
Then the cDNA was amplified by Real-time PCR with
the SYBR PrimeScript RT-PCR kit (Takara, Dalian,
China) with the following primers (synthesized by Sang-
gon Corporation, Shanghai, China): b-actin, 5’-TGA
CGG GGT CAC CCA CAC TGT GCC CAT CTA-
3’(forward), 5’-CTA GAA GCA TTG CGG TCG ACG
ATG GAG GG-3’(backward); HIF-1a,5 ’-CTC AAA
GTC GGA CAG CCT CA-3’(forward), 5’-CCC TGC
A G TA G GT T TC T GC T - 3 ’(backward); CAIX[31],
5’-CTT GGA AGA AAT CGC TGA GG-3’(forward),
5’-TGG AAG TAG CGG CTG AAG TC-3’ (backward);
BNIP3[31], 5’- T G CT G CT C TC T CA T TT G CT G - 3 ’
(forward), 5’-GAC TCC AGT TCT TCA TCA AAA
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Page 9 of 11GGT-3’(backward); and VEGF[31], 5’-CTA CCT CCA
C C AT G CC A AG T - 3 ’(forward), 5’-CCA CTT CGT
G A TG A TT C TG C - 3 ’(backward). The alteration of
mRNA expression in cells treated with or without trip-
tolide was assessed by delta delta Ct method [45].
ELISA assays for VEGF secretion
The amount of secreted VEGF was tested as described
previously [46]. The medium was replaced with 1.5 mL/
well of fresh medium, and the cells were subjected to
hypoxia or normoxia in the presence or absence of trip-
tolide at the indicated concentrations for 12 h. Then,
the cell supernatants were collected, clarified by centri-
fugation at 1,000 g for 5 min, and stored at -20°C.
VEGF in the supernatant was determined with a VEGF-
ELISA kit according to the manufacturer’si n s t r u c t i o n s
(Jingmei Biotech Co, Beijing, China). Results were nor-
malized to the cell number.
Small interfering RNA (siRNA) transfection
siRNAs (HIF-1a siRNA-1 targeting 5’-CUG AUG ACC
AGC AAC UUG ATT-3’ [47], HIF-1a siRNA-2 target-
ing 5’ -GCU CAA UUU AUG AAU AUU ATT-3’,H I F -
1a siRNA-3 targeting 5’-GAA GGA ACC UGA UGC
UUU ATT-3’ and GFP (scrambled) siRNA targeting
5’-GAC CCG CGC CGA GGU GAA GTT-3’)w e r e
obtained from GenePharma (Shanghai, China). The
transfection with siRNA was conducted with Lipofecta-
mine RNAimax (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. After 24 h, the cells
were treated with or without triptolide for the indicated
time.
Flow cytometry
SKOV-3 cells (2 × 10
5)t r a n s f e c t e dw i t hH I F - 1 a siRNA
or GFP siRNA were seeded into 6-well plates overnight
and then treated with or without triptolide for 36 h.
Apoptosis was analyzed by flow cytometry [48]. The
sub-G1 cells were considered as apoptotic cells.
Rat aortic ring assays
Rat aortic ring assays were performed as described before
[49]. The aortas were harvested from 6-week-old-aged
Sprague-Dawley rats. Each aorta was cut into 1-mm slices
and embedded in 30 μL Matrigel in 24-well plates. The
aortic rings were then fed with 500 μL of M199 medium
(10% FCS) with different concentrations of triptolide or
the solvent control. After 5-d incubation at 37°C in a
CO2 incubator, each aorta was photographed.
Data Analyses
Data were presented as mean ± SD, and differences
were considered significant when P < 0.05 as deter-
mined by Student’s t test.
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